Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

PARLuNET : Phase 1 Trial of PARP Inhibitor Combined With 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Metastatic NeuroEndocrine Tumor

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Radiotherapy<br/>TrialTypeRadiotherapy
Trial

OnePhase One

18+Age Over 18

Advanced CancersCancer LocationMulti-Cancer
Trial

Radiotherapy,Systemic therapy | Blood / Myeloma / Lymphoma,Bowel (colorectum),Brain and spinal cord,Breast,CUP,Female reproductive organs,Head and neck,Lung,Sarcoma,Skin,Stomach and upper gastrointestinal tract,Urinary systemNeuroendocrine tumours,Pancreas

Trial Overview Read MoreRead more

This phase I trial is evaluating how safe and tolerable a targeted therapy (talazoparib) is in combination with radionuclide therapy (177Lu-DOTA-Octreotate) in people with metastatic pancreatic neuroendocrine cancer.
 

This trial is treating patients with pancreatic neuroendocrine tumours.

This is a systemic and radiation therapy trial.

You may be able to join this trial if:

  • You are able to swallow medication by mouth.
  • Your cancer has spread to other parts of the body.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have had certain treatments, surgical procedures or drugs.
  • You have previously been treated (or are currently being treated) on a clinical trial.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

Phase 1 Trial of PARP Inhibitor Combined With 177Lu-DOTA-Octreotate Peptide Receptor Radionuclide Therapy (PRRT) in Patients With Metastatic NeuroEndocrine Tumor

Other Non-Commercial Sponsor

Peter MacCallum Cancer Centre

Summary

All eligible participants will receive 4 cycles of 177Lu-DOTA-Octreotate peptide receptor radionuclide therapy (PRRT) every 8 weeks, with the last 3 cycles being combined with talazoparib. Talazoparib will be administered in escalating doses, orally, daily during days 2-6 of these cycles.

Recruiting Hospitals Read MoreRead more

Peter MacCallum Cancer Centre, Molecular Imaging
Parkville
Dr Annette Hogg
annette.hogg@petermac.org
03 9656 3744

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next